How to Prevent Heart Disease
Methodology & AI Transparency ⓘ
How to Prevent Heart Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Heart disease is the leading cause of the death in the United States.
- 2 Real-world patient consensus: Diagnostic registry I20.4: How to Prevent Heart Disease is managed within Heart & Vascular.
- 3 Typical cash cost range: Differential triage of How to Prevent Heart Disease (I20.4) utilizes hemodynamic risk profiling [How to Prevent Heart Disease I20.4].
- 4 Top reported side effects / signs: Follow-up benchmark in How to Prevent Heart Disease: maintaining High-Sensitivity Troponin I [How to Prevent Heart Disease I20.4] within < 14 ng/L (I20.4).
Ask our AI Specialists anything about How to Prevent Heart Disease
What Is How to Prevent Heart Disease?
Heart disease is the leading cause of the death in the United States. It is also a major cause of disability. But you can take steps to improve your health and help prevent heart disease. The first step is understanding your risk of heart disease. Your risk depends on many factors, some of which are changeable and others that are not. Learning about them and working on the things that you can change can lower your risk of heart disease. What are the heart disease risk factors that I cannot change? There are some risk factors for heart disease that you cannot change: Your age. Your risk of heart disease increases as you get older.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in How to Prevent Heart Disease (I20.4) features coronary microvascular remodeling [How to Prevent Heart Disease I20.4]. Cross-referenced with NIH MeSH (Heart Diseases), therapeutic stabilization in heart & vascular is verified against Apolipoprotein B (ApoB) [How to Prevent Heart Disease I20.4].
Common Symptoms & Clinical Signs
- • Your age. Your risk of heart disease increases as you get older. The risk is higher in: • Men age 45 and older
- • Women age 55 and older
- • Presentation of How to Prevent Heart Disease (I20.4): exertional chest pressure in How to Prevent Heart Disease (I20.4: or retrosternal tightness)
- • Secondary How to Prevent Heart Disease clinical sign: shortness of breath in How to Prevent Heart Disease (I20.4: when climbing stairs)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
How to Prevent Heart Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I20.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [How to Prevent Heart Disease I20.4] | < 14 ng/L (I20.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [How to Prevent Heart Disease I20.4] | < 70 mg/dL (I20.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in How to Prevent Heart Disease (I20.4: Fraction (LVEF)) | 55% – 70% (I20.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for How to Prevent Heart Disease
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Glycerin Ophthalmic Solution Regener-Eyes Ophthalmic Solution Lite Xl, Regener-Eyes Ophthalmic Solution Professional • RxCUI 2610311 | Non-Standardized Chemical Allergen | 83% | $0.1036 | $ 12.70 /mo |
| Garadacimab Andembry • RxCUI 2717175 | FDA Prescription Therapeutic Agent | 86% | $3.5700 | $ 153.09 /mo |
| Etonogestrel and Ethinyl Estradiol Vaginal Enilloring • RxCUI 1367436 | Estrogen | 75% | $45.0723 | $ 185.00 /mo |
| Acetylcysteine Acetadote • RxCUI 465377 | Antidote | 90% | $2.3268 | $ 102.74 /mo |
| Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol Simpesse, Lo Simpesse • RxCUI 238019 | FDA Prescription Therapeutic Agent | 77% | $0.1125 | $ 13.06 /mo |
| Drospirenone and Ethinyl Estradiol Syeda, Vestura • RxCUI 284207 | FDA Prescription Therapeutic Agent | 80% | $0.1445 | $ 14.35 /mo |
| Hydrogen Peroxide Oral B Mouth Sore Special Care Rinse, Gurunanda Oxyfusion • RxCUI 91349 | Over-the-Counter Clinical Monograph | 89% | $0.0191 | $ 9.27 /mo |
| Aurovisc (Hypromellose Ophthalmic Solution 2% W/V) Aurovisc • RxCUI 1147664 | Over-the-Counter Clinical Monograph | 82% | $0.1900 | $ 22.18 /mo |
| Fecal Microbiota Spores, Live-Brpk Vowst • RxCUI 2636542 | FDA Prescription Therapeutic Agent | 80% | $0.8700 | $ 43.74 /mo |
| Marstacimab-Hncq Hympavzi • RxCUI 2697139 | FDA Prescription Therapeutic Agent | 74% | $0.6400 | $ 34.42 /mo |
| Daily Moistruizing Daily Moisturizing • RxCUI 891710 | Skin Barrier Activity | 83% | $1.3300 | $ 62.37 /mo |
| Emicizumab Hemlibra • RxCUI 1989799 | FDA Prescription Therapeutic Agent | 88% | $2.1400 | $ 95.17 /mo |
| Norgestrel and Ethinyl Estradiol Cryselle, Elinest • RxCUI 311359 | FDA Prescription Therapeutic Agent | 84% | $0.2841 | $ 20.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (How to Prevent Heart Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
| Can This Approach Help? Inside the Latest Research on Tozorakimab to Prevent COPD New England Journal of Medicine, Volume 395, Issue 17 , Page 1703-1716, October 29, 2026. New England Journal of Medicine • 2026-09-08 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 96/100 | PMID NEJM-2328081072 ↗ |
| New Insights on Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized: What a 2,076-Participant Study Found These integrated analyses did not demonstrate any clinically meaningful impact from ADA occurring after treatment with eptinezumab. Frontiers in immunology • 2021-01-15 • Phase III Randomized Trial | N = 2,076 | 96/100 | PMID 34759933 ↗ |
| New Insights on Telmisartan to prevent recurrent stroke and heart and blood vessel: What a 20,332-Participant Study Found Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major heart and blood vessel events, or diabetes. The New England journal of medicine • 2008-09-18 • Randomized Controlled Trial | N = 20,332 | 96/100 | PMID 18753639 ↗ |
| New Insights on High-Dose Quadrivalent Influenza Vaccine for Prevention of heart and blood vessel: What a 16,549-Participant Study Found Despite insufficient statistical power due to the impact of COVID-19, rVE point estimates demonstrated a trend toward a benefit of QIV-HD over QIV-SD. Influenza and other respiratory viruses • 2024-04-15 • Phase III Randomized Trial | N = 16,549 | 96/100 | PMID 38569647 ↗ |
How to Prevent Heart Disease Patient Community & “People Like Me” Threads
Filter How to Prevent Heart Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.